Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaHepatotoxicity Secondary to ChemotherapyInhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitorsIncidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.Activation of platelet-derived growth factor receptor alpha contributes to liver fibrosisHepatotoxicity of molecular targeted therapy.Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysisHepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.Drug-induced liver injury: what was new in 2013?Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review.Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer.Incidence and risk of regorafenib-induced hepatotoxicity.Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines.Ibrutinib-induced acute liver failure.Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.Targeted Therapy for Medullary Thyroid Cancer: A Review.Mitochondrial pathway-mediated apoptosis is associated with erlotinib-induced cytotoxicity in hepatic cells.Drug-induced liver injury in Oncology.Regorafenib induced severe toxic hepatitis: characterization and discussion.Hepatotoxicity in Advanced Lung Adenocarcinoma: A Retrospective Study of 2108 Cases.Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.[Drug induced hepatotoxicity in targeted therapy for lung cancer].Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
P2860
Q26749324-08060B8A-08D6-40E8-B3AA-4AFB9838FB35Q26861560-BFF81AE6-FA27-4144-9141-15F1B1C5C040Q28239708-2A5D28BB-4E5B-4B4F-8528-AC1689BA2F46Q33887946-22EBD4A0-A99D-4BDB-9AB9-C89308CBCE29Q34484368-73260C1D-CC34-4F19-B1C6-AA20A99DAE4AQ35131124-30EF5105-6116-4F9A-AEAF-AEF11E192B51Q35648962-C9E07570-79D8-4DCD-BB29-BE7257E9F746Q35819331-4373E653-1842-4795-A9DD-5132319EA301Q36024704-ED63EC60-B39C-4E77-BE73-A83EBCC4CC7BQ38101884-A4187562-102B-417D-9D64-8297402CB9FAQ38205591-56B4596B-05D1-4390-8646-4608CC8BA00EQ38268600-CB0F9D4D-7E1D-4F67-9CF5-3490F48F05EAQ38993878-111747A3-604E-4562-94CB-E419A5A280FBQ41928458-9A1176B0-A1DC-47F8-BE64-BB1B95F207CAQ45800216-0C36C902-AEE6-4CFD-9134-F5A0047DCF44Q46274363-AD410694-3CD8-4580-ADEE-EBBEDB235853Q48150752-A10749CD-40CE-4940-BD51-17C3C664FBAEQ48192170-0175E020-CC6D-422A-8738-8A422AE5B059Q49328959-9F2AC470-CC99-4A3B-87D1-D76AB5C11C74Q49727278-F705E7FF-CAE9-416D-A8F8-0B3C72874294Q50662188-DA0E71AA-6C03-4058-A411-A5D5954E3C82Q51585580-C7649E9C-65E6-4FA9-A74A-7CD138187405Q54109904-44DC8424-DF82-4FE9-87DB-CDBD917D7402Q54123036-9280A91F-6703-4AAF-9E37-E3C75BD870C7Q54977664-12C7A658-3E36-4AF3-BBAE-98F57B8DFD83Q55071041-079541F8-C656-420A-B93C-7F35213E9E95Q58788266-F8EB3DCB-8208-4F08-9D93-7F43900781D3
P2860
Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Risk of tyrosine kinase inhibi ...... cer patients: a meta-analysis.
@en
Risk of tyrosine kinase inhibi ...... cer patients: a meta-analysis.
@nl
type
label
Risk of tyrosine kinase inhibi ...... cer patients: a meta-analysis.
@en
Risk of tyrosine kinase inhibi ...... cer patients: a meta-analysis.
@nl
prefLabel
Risk of tyrosine kinase inhibi ...... cer patients: a meta-analysis.
@en
Risk of tyrosine kinase inhibi ...... cer patients: a meta-analysis.
@nl
P1476
Risk of tyrosine kinase inhibi ...... ncer patients: a meta-analysis
@en
P2093
Han Kiat Ho
Yi Ling Teo
P304
P356
10.1016/J.CTRV.2012.09.004
P577
2012-10-23T00:00:00Z